Latest Period
Q4 2025
Security Snapshot
Vir Biotechnology, Inc. - Common Stock (VIR) Institutional Ownership
CUSIP: 92764N102
13F Institutional Holders and Ownership History from Q4 2019 to Q1 2026
Institutions Reporting
217
Shares (Excl. Options)
115,545,961
Price
$6.03
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock
- Symbol
- VIR on Nasdaq
- Shares outstanding
- 159,883,161
- Price per share
- $9.52
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 115,545,961
- Total reported value
- $696,530,447
- % of total 13F portfolios
- 0%
- Share change
- -1,210,183
- Value change
- -$6,968,225
- Number of holders
- 217
- Price from insider filings
- $9.52
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- VIR - Vir Biotechnology, Inc. - Common Stock is tracked under CUSIP 92764N102.
- 217 institutions reported positions in Q4 2025.
- 4 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 217 to 175 between Q4 2025 and Q1 2026.
- Reported value moved from $696,530,447 to $678,818,000.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 217 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 92764N102?
CUSIP 92764N102 identifies VIR - Vir Biotechnology, Inc. - Common Stock in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 92764N102:
Significant Owners of Vir Biotechnology, Inc. - Common Stock (VIR) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BlackRock, Inc. | 11% | $93,255,785 | 14,826,039 | BlackRock, Inc. | 31 Mar 2025 | |||
| ARCH Venture Fund IX, L.P. | 8.5% | $101,645,627 | 13,534,704 | Robert Nelsen | 27 Feb 2026 | |||
| SB INVESTMENT ADVISERS (UK) LTD | 9.4% | $77,652,504 | 13,116,977 | SB Investment Advisers (UK) Limited | 31 Dec 2025 | |||
| VANGUARD PORTFOLIO MANAGEMENT LLC | 5.8% | $82,944,826 | 9,257,235 | Vanguard Portfolio Management | 31 Mar 2026 |
As of 31 Dec 2025, 217 institutional investors reported holding 115,545,961 shares of Vir Biotechnology, Inc. - Common Stock (VIR). This represents 72% of the company’s total 159,883,161 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Vir Biotechnology, Inc. - Common Stock (VIR) together control 60% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | 10% | 16,330,103 | +2.3% | 0% | $98,470,521 |
| SB INVESTMENT ADVISERS (UK) LTD | 8.2% | 13,116,977 | -21% | 0.79% | $79,095,371 |
| ARCH Venture Management, LLC | 8.1% | 12,916,663 | 0% | 12% | $77,887,478 |
| VANGUARD GROUP INC | 7.8% | 12,548,944 | -2% | 0% | $75,670,133 |
| GSK plc | 5.3% | 8,550,954 | 0% | 6.5% | $51,562,253 |
| STATE STREET CORP | 3.9% | 6,229,555 | +19% | 0% | $37,564,217 |
| FMR LLC | 2% | 3,158,416 | -13% | 0% | $19,045,246 |
| MORGAN STANLEY | 1.7% | 2,679,145 | -0.37% | 0% | $16,155,254 |
| DIMENSIONAL FUND ADVISORS LP | 1.6% | 2,536,277 | -15% | 0% | $15,292,107 |
| ORBIMED ADVISORS LLC | 1.5% | 2,380,715 | 0% | 0.31% | $14,355,711 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.5% | 2,328,207 | +3.6% | 0% | $14,041,408 |
| GOLDMAN SACHS GROUP INC | 0.98% | 1,568,904 | +3.1% | 0% | $9,460,491 |
| Aberdeen Group plc | 0.87% | 1,390,577 | -8.9% | 0.01% | $8,385,179 |
| Balyasny Asset Management L.P. | 0.86% | 1,368,474 | 0.02% | $8,251,898 | |
| Hudson Bay Capital Management LP | 0.83% | 1,325,000 | +45% | 0.05% | $7,989,750 |
| Candriam S.C.A. | 0.65% | 1,031,663 | 0.03% | $6,221,193 | |
| MILLENNIUM MANAGEMENT LLC | 0.63% | 1,002,606 | -28% | 0% | $6,045,714 |
| BANK OF AMERICA CORP /DE/ | 0.58% | 930,908 | +132% | 0% | $5,613,376 |
| GordonMD Global Investments LP | 0.58% | 930,317 | 0% | 4% | $5,609,812 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.57% | 904,480 | -21% | 0% | $5,454,014 |
| NORTHERN TRUST CORP | 0.53% | 848,469 | -6.5% | 0% | $5,116,269 |
| AMERIPRISE FINANCIAL INC | 0.46% | 731,307 | +276% | 0% | $4,409,781 |
| Boxer Capital Management, LLC | 0.39% | 625,000 | 0.82% | $3,768,750 | |
| RENAISSANCE TECHNOLOGIES LLC | 0.38% | 614,464 | -47% | 0.01% | $3,705,218 |
| NORDEA INVESTMENT MANAGEMENT AB | 0.38% | 609,726 | -15% | 0% | $3,545,556 |
Institutional Holders of Vir Biotechnology, Inc. - Common Stock (VIR) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 75,766,582 | $678,818,000 | +$118,797,750 | $8.96 | 175 |
| 2025 Q4 | 115,545,961 | $696,530,447 | -$6,968,225 | $6.03 | 217 |
| 2025 Q3 | 107,007,241 | $610,804,612 | -$19,864,830 | $5.71 | 209 |
| 2025 Q2 | 110,838,661 | $558,775,027 | +$84,580,503 | $5.04 | 211 |
| 2025 Q1 | 93,307,654 | $604,780,740 | +$27,869,791 | $6.48 | 230 |
| 2024 Q4 | 88,707,515 | $651,126,620 | +$14,506,884 | $7.34 | 202 |
| 2024 Q3 | 87,600,991 | $656,230,226 | -$4,592,687 | $7.49 | 195 |
| 2024 Q2 | 88,056,992 | $783,680,407 | -$9,558,987 | $8.90 | 213 |
| 2024 Q1 | 88,814,549 | $899,654,431 | +$7,160,790 | $10.13 | 205 |
| 2023 Q4 | 88,171,139 | $887,025,787 | +$1,493,653 | $10.06 | 202 |
| 2023 Q3 | 88,255,499 | $826,977,393 | -$227,669,705 | $9.37 | 212 |
| 2023 Q2 | 90,761,353 | $2,226,351,489 | +$60,012,170 | $24.53 | 222 |
| 2023 Q1 | 88,385,448 | $2,056,730,043 | +$54,021,550 | $23.27 | 226 |
| 2022 Q4 | 86,118,572 | $2,179,650,166 | -$15,704,818 | $25.31 | 219 |
| 2022 Q3 | 86,915,381 | $1,675,900,472 | -$11,606,508 | $19.28 | 208 |
| 2022 Q2 | 86,086,454 | $2,193,070,491 | +$146,002,800 | $25.47 | 201 |
| 2022 Q1 | 81,103,450 | $2,086,374,530 | -$14,155,763 | $25.72 | 191 |
| 2021 Q4 | 78,095,522 | $3,252,220,942 | +$158,691,641 | $41.87 | 203 |
| 2021 Q3 | 74,464,481 | $3,240,626,324 | -$19,547,865 | $43.52 | 169 |
| 2021 Q2 | 74,156,851 | $3,506,017,317 | +$66,755,814 | $47.28 | 156 |
| 2021 Q1 | 75,409,279 | $3,865,770,922 | -$99,056,866 | $51.27 | 151 |
| 2020 Q4 | 76,141,156 | $2,039,280,477 | +$150,971,873 | $26.78 | 136 |
| 2020 Q3 | 70,048,123 | $2,405,706,821 | +$553,884,772 | $34.33 | 117 |
| 2020 Q2 | 53,528,634 | $2,192,860,452 | +$657,421,714 | $40.97 | 109 |
| 2020 Q1 | 37,861,951 | $1,297,525,769 | -$4,041,452 | $34.27 | 61 |
| 2019 Q4 | 36,584,366 | $460,028,000 | +$460,028,135 | $12.57 | 38 |